3
Announcements
Trials
Browse
Landscape
Phase
Phase 2
1
Status
Recruiting
1
Sponsor Class
OTHER
1
Study Type
Interventional
1
Sponsor
Cancer Type
Gastrointestinal
1
Conditions
Polycystic Ovary Syndrome
21
Glioblastoma
5
Endometrial Neoplasms
5
Breast Neoplasms
5
Neoplasms
4
Squamous Cell Carcinoma of Head and Neck
3
Prostatic Neoplasms
3
Leukoplakia, Oral
3
Insulin Resistance
3
Ovarian Neoplasms
2
Metabolic Syndrome
2
Metabolic Diseases
2
Medulloblastoma
2
Infertility
2
Erythroplasia
2
Carcinoma, Non-Small-Cell Lung
2
Carcinoma, Intraductal, Noninfiltrating
2
Adenocarcinoma Of Esophagus
2
Weight Loss
1
Uterine Cervical Neoplasms
1
Urothelial Cancer
1
Thyroid Diseases
1
TP53 Y220C Mutation
1
Smoldering Multiple Myeloma
1
Sarcoma
1
Rectal Neoplasms
1
Prostate Cancer Recurrent
1
Prediabetic State
1
Posterior Fossa Ependymal Tumor
1
Pleural Effusion, Malignant
1
Interventions
Oxaliplatin
19
pembrolizumab
13
Fluorouracil
12
Leucovorin
11
Capecitabine
11
Paclitaxel
10
Gemcitabine
8
Docetaxel
8
zolbetuximab
6
cemiplimab
6
Cisplatin
6
Albumin-Bound Paclitaxel
6
durvalumab
5
Ramucirumab
5
Radiotherapy
5
Irinotecan
4
Cyclophosphamide
4
130-nm albumin-bound paclitaxel
4
trastuzumab deruxtecan
3
tislelizumab
3
lenvatinib
3
enzalutamide
3
darolutamide
3
Trastuzumab
3
Taxes
3
S 1 (combination)
3
Radiosurgery
3
Pemetrexed
3
Nivolumab
3
Carboplatin
3
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Adenocarcinoma
×
Metformin
×
1 year
×
Clear all
NCT06687876
2025-07-10
MEMENTO
Amsterdam UMC, location VUmc
Phase 2
Recruiting
14 enrolled